ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1322

Evaluation of Intra-articular CNTX-4975 in Subjects with Painful Bilateral Knee Osteoarthritis: Effects on Pain with Walking and Patient Impression of Change in Pain

Randall Stevens 1, Kimberly Guedes 1, Nilam Mistry 1, Paul Tiseo 2, Duncan Lascelles 3, Mario Mendoza1 and David Ball 4, 1Centrexion Therapeutics Corp, Boston, MA, 2Centrexion Therapeutics Corp, Boston, 3Translational Research in Pain, North Carolina State University, Raleigh, NC, 4MAC Clinical Research, Manchester, United Kingdom

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Knee, Osteoarthritis, pain management and patient-reported outcome measures

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 11, 2019

Session Title: Osteoarthritis – Clinical Poster I

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: A double-blind, randomized, placebo-controlled trial (TRIUMPH; NCT02558439) with a single 1 mg intra-articular (IA) injection of CNTX-4975 (highly purified trans-capsaicin) into one knee for management of moderate to severe pain associated with knee osteoarthritis (OA) revealed a statistically significant and clinically meaningful decrease in pain with walking vs placebo through 24 weeks post-dose. The present open-label study (NCT03472677) evaluated the efficacy and safety of a prefilled syringe with an aqueous formulation of CNTX-4975. Presented here are the 6-week outcomes after bilateral CNTX-4975 injections.

Methods: Subjects (aged 45-75 y) with bilateral moderate to severe painful knee OA (numeric pain rating scale [NPRS, 0–10]) score of 4–9 inclusive required for enrollment) for ≥3 months before study entry received a single IA injection of CNTX-4975 1 mg into each knee, with 7 days (±2 days) between injections. ACR criteria were met by 67% of subjects for knee OA as assessed by knee pain, radiographic findings, and age >50 y; the other 33% had pain and radiographic findings, but were aged 47–49 y. IA lidocaine 2% (without epinephrine, 15 mL) was given 3–30 minutes before injection of CNTX-4975. Skin around the knee was cooled before lidocaine injection and throughout the procedure using different methods, and temperature changes in the knee joint were documented with an IA temperature probe. Pain with walking over the previous 24 hours was rated by the NPRS at baseline and at 6 weeks (trial end). Subjects also rated the change in pain in each knee using the Patient Global Impression of Change (PGIC) scale (7-point categorical scale from very much worse to very much improved). Knees were examined to determine the presence of injection site reactions, and adverse events were recorded.

Results: Fifteen subjects (30 knees) with bilateral knee OA (12 male, 3 female; mean age, 57 y) were enrolled and completed the study. Baseline and day 42 NPRS scores were averaged across both knees. At 6 weeks, pain rating by NPRS was reported as 0 in 13 of 30 assessments (15 subjects, both knees), and pain score was reported as ≤3 of 10 for 26 of 30 knees. A similar pattern of improvement was evident with the PGIC (Table): in 26 of 30 recordings, subjects described pain at trial end as much or very much improved. No subject reported pain as being unchanged or worse in either knee. Treatment-emergent adverse events (TEAEs) reported on the day of injection were nausea (n=3), headache (n=2), vasovagal attack, dizziness, elevated blood pressure, and tachycardia (n=1 each); all were reported as mild with 2 (vasovagal attack and 1 report of nausea) deemed possibly related to treatment. TEAEs reported after the day of injection were insect bite (n=2) and hay fever, vasovagal attack, back pain, acid reflux (esophageal), allergic conjunctivitis, and bruise (n=1 each); all were mild and deemed unlikely or not related to study treatment.

Conclusion: Pain in bilateral osteoarthritic knees was rated much or very much improved in 87% of assessments, and >40% of knees were reported pain free at 5–6 weeks post CNTX-4975 injection.


Disclosure: R. Stevens, Centrexion Therapeutics Corp, 3, 4; K. Guedes, Centrexion Therapeutics Corp, 3; N. Mistry, Centrexion Therapeutics Corp, 3; P. Tiseo, Centrexion Therapeutics Corp, 3; D. Lascelles, Centrexion Therapeutics Corp, 9; M. Mendoza, Centrexion Therapeutics Corp, 3; D. Ball, None.

To cite this abstract in AMA style:

Stevens R, Guedes K, Mistry N, Tiseo P, Lascelles D, Mendoza M, Ball D. Evaluation of Intra-articular CNTX-4975 in Subjects with Painful Bilateral Knee Osteoarthritis: Effects on Pain with Walking and Patient Impression of Change in Pain [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/evaluation-of-intra-articular-cntx-4975-in-subjects-with-painful-bilateral-knee-osteoarthritis-effects-on-pain-with-walking-and-patient-impression-of-change-in-pain/. Accessed January 21, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-intra-articular-cntx-4975-in-subjects-with-painful-bilateral-knee-osteoarthritis-effects-on-pain-with-walking-and-patient-impression-of-change-in-pain/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.